ImmunoPET
ImmunoPET is a nuclear imaging technology that enables visualization of the ADC’s target throughout the patient’s body, including all metastatic sites, providing complementary information to tumor biopsy and AI analysis. This technique is based on the injection of an antibody labeled with a radioactive tracer.
⟶ A non-invasive method essential for understanding how the distribution of the target throughout the body impacts the response to the ADC.
ImmunoPET is a cutting-edge nuclear imaging technique that combines the specificity of monoclonal antibodies with the sensitivity of PET scanning to non-invasively visualize the distribution of a drug target throughout the entire body. This approach is particularly useful in assessing Antibody-Drug Conjugates (ADCs), allowing clinicians and researchers to map where the target antigen is expressed across both primary tumors and metastatic lesions. Unlike a single-site biopsy, ImmunoPET provides a whole-body perspective on target presence and heterogeneity, offering valuable insights into potential response, resistance, or off-target effects—thus guiding personalized treatment strategies.
How does it work?
The process begins with the selection of an antibody that specifically binds the target of interest. This antibody is then radiolabeled with a positron-emitting isotope such as zirconium-89, enabling its detection via PET. After intravenous injection, the radiolabeled antibody circulates and binds to target-expressing tissues. A PET scan performed after appropriate uptake time generates a high-resolution, 3D image of antibody distribution. The result is a quantitative, non-invasive tool that complements tissue biopsy and AI-based analytics, helping clinicians better understand drug-target interactions at the whole-body level.